Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 4/20 | 0.32 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.32 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19920880 | 1.00 | DNM1 (0.40) | DNM1LMNACA2OPRM1TSHR | |
| SCHEMBL19922801 | 1.00 | DNM1 (0.40) | DNM1LMNACA2OPRM1TSHR | |
| SCHEMBL19920881 | 0.97 | DNM1 (0.36) | DNM1LMNACA2OPRM1TSHR | |
| SCHEMBL2139902 | 0.95 | LMNA (0.41) | DNM1LMNAOPRM1TSHRTHRB | |
| SCHEMBL3395197 | 0.95 | LMNA (0.41) | DNM1LMNAOPRM1TSHRTHRB | |
| SCHEMBL290240 | 0.95 | LMNA (0.41) | DNM1LMNAOPRM1TSHRTHRB | |
| SCHEMBL1699698 | 0.95 | LMNA (0.41) | DNM1LMNAOPRM1TSHRTHRB | |
| SCHEMBL11285372 | 0.95 | LMNA (0.41) | DNM1LMNAOPRM1TSHRTHRB | |
| SCHEMBL2139776 | 0.95 | LMNA (0.41) | DNM1LMNAOPRM1TSHRTHRB | |
| SCHEMBL2140719 | 0.95 | LMNA (0.41) | DNM1LMNAOPRM1TSHRTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118201905-A | Cationic lipid | 武田药品工业株式会社 | 2024-06-14 | — | — | CN | disclosed |
| CN-117062875-A | Polycarbonate resin composition | 三菱工程塑料株式会社 | 2023-11-14 | — | — | CN | disclosed |
| WO-2023085299-A1 | CATIONIC LIPID | 武田薬品工業株式会社 | 2023-05-19 | — | — | WO | disclosed |
| EP-1937734-B1 | BIOCIDAL POLYMERS | KE KELIT KUNSTSTOFFWERK GES M B H (AT) | 2018-04-04 | — | — | EP | disclosed |
| EP-3082720-A1 | ANHYDROUS ANTIPERSPIRANT COMPOSITION IN AEROSOL FORM COMPRISING AN ANTIPERSPIRANT ACTIVE AGENT AND A WATER-INSOLUBLE FILM-FORMING BLOCK ETHYLENIC POLYMER | L'Oréal (FR) | 2016-10-26 | — | — | EP | disclosed |
| EP-3010473-A2 | OXIDATION DYEING PROCESS USING A COMPOSITION COMPRISING AN AMINOBENZIMIDAZOLONE OXIDATION BASE AND A METAL CATALYST | L'OREAL (FR) | 2016-04-27 | — | — | EP | disclosed |
| EP-2950774-A2 | DYE COMPOSITION USING AT LEAST ONE COUPLER OF META-PHENYLENEDIAMINE TYPE SUBSTITUTED IN POSITION 4 IN A MEDIUM COMPRISING A FATTY SUBSTANCE, PROCESSES AND DEVICE | L'Oréal (FR) | 2015-12-09 | — | — | EP | disclosed |
| EP-2925413-A1 | COSMETIC WATER-IN-OIL EMULSION, IN PARTICULAR PACKAGED IN AEROSOL FORM, COMPRISING AT LEAST ONE VINYL POLYMER CONTAINING AT LEAST ONE CARBOSILOXANE DENDRIMER-BASED UNIT, AT LEAST ONE OLEFIN COPOLYMER AND AT LEAST ONE ANTIPERSPIRANT ACTIVE AGENT | L'Oréal (FR) | 2015-10-07 | — | — | EP | disclosed |
| WO-2015091742-A1 | ANHYDROUS ANTIPERSPIRANT COMPOSITION IN AEROSOL FORM COMPRISING AN ANTIPERSPIRANT ACTIVE AGENT AND A WATER-INSOLUBLE FILM-FORMING BLOCK ETHYLENIC POLYMER | L'OREAL (FR) | 2015-06-25 | — | — | WO | disclosed |
| EP-2846761-A2 | COMPOSITION COMPRISING (2,5-DIAMINOPHENYL)ETHANOL, AN ALKYLPOLYGLUCOSIDE NONIONIC SURFACTANT, AN OXYETHYLENATED SORBITAN ESTER OR A POLYALKOXYLATED OR POLYGLYCEROLATED FATTY ALCOHOL IN A MEDIUM RICH IN FATTY SUBSTANCES, DYEING PROCESS AND DEVICE THEREFORE | L'OREAL (FR) | 2015-03-18 | — | — | EP | disclosed |
| EP-2416660-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | Infinity Pharmaceuticals, Inc. (US) | 2012-02-15 | — | — | EP | disclosed |
| EP-2406213-A1 | NITRATION OF TETRACYCLINES | Wyeth LLC (US) | 2012-01-18 | — | — | EP | disclosed |
| WO-2011157796-A1 | COSMETIC COMPOSITION COMPRISING A BRANCHED SULPHONIC POLYESTER AND A PARTICULAR THICKENER AND USES IN HAIR STYLING | L'OREAL (FR) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011107468-A2 | COSMETIC ANTIDANDRUFF COMPOSITION BASED ON ELLAGIC ACID OR A DERIVATIVE THEREOF AND A SECOND, DIFFERENT ACTIVE COMPOUND IN A SPECIFIC WEIGHT RATIO | L'OREAL (FR) | 2011-09-09 | — | — | WO | disclosed |
| US-20110172186-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. | 2011-07-14 | — | — | US | disclosed |
| EP-2282742-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | Infinity Pharmaceuticals, Inc. (US) | 2011-02-16 | — | — | EP | disclosed |
| US-20110028455-A1 | Indole-substituted 3-cyanopyridines As Kinase Inhibitors | WYETH LLC (US) | 2011-02-03 | — | — | US | disclosed |
| US-20080251460-A1 | Biocidal Polymers | KE KELIT KUNSTSTOFFWERK GESMBH (AT) | 2008-10-16 | — | — | US | disclosed |
| EP-1937734-A2 | BIOCIDAL POLYMERS | KE-KELIT Kunststoffwerk Gesellschaft m.b.H. (AT) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007045634-A2 | BIOCIDAL POLYMERS | KE KELIT KUNSTSTOFFWERK GESMBH (AT) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172186-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, ASAH1 | DNM1 2874/4885LMNA 4025/4885CA2 1487/4885 |
| US-20110028455-A1 | Indole-substituted 3-cyanopyridines As Kinase Inhibitors | CNKSR1, CSNK1G3, GRK3 | DNM1 4736/4885LMNA 3611/4885CA2 1241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.